OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
January 01, 2012
Industry Forecast 2012 : Bridging the Divide
Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas.
Hungary's high-quality infrsatructure, highly skilled labor force, and central geographic location have turned the country into an attractive destination for investment.
William Looney looks at how Big Pharma is attempting to bridge the emerging markets' widening cancer divide.
The use and study of DDW by the Hungarian medical community
Look for action in 2012 on drug access, shortages, innovation, and transparency.
A quick chat with CMO of Assign Group Dr. Kata Mazalin
It's a disturbing irony: In an industry whose entire economic value is founded on its ability to innovate, why is there so much discomfort with the risk required for innovation. Where did the courage to innovate go?
A selection of the recent breakthrough technologies showcased at the Cleveland Clinic's Medical Innovations Summit.
A key consideration under the Affordable Care Act is how states select plans for drug coverage.
Mason Tenaglia offers empirical defense of coupons and copay offset programs.
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science.
How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all?
Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential.